Pfizer Inc. (PFE)
30.03
-0.39
(-1.28%)
USD |
NYSE |
Oct 23, 16:00
30.03
0.00 (0.00%)
After-Hours: 20:00
Pfizer Enterprise Value : 222.94B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 222.94B |
| October 22, 2026 | 225.16B |
| October 21, 2026 | 221.91B |
| October 20, 2026 | 223.39B |
| October 19, 2026 | 219.58B |
| October 16, 2026 | 220.37B |
| October 15, 2026 | 219.58B |
| October 14, 2026 | 218.26B |
| October 13, 2026 | 213.48B |
| October 12, 2026 | 213.65B |
| October 09, 2026 | 212.96B |
| October 08, 2026 | 210.34B |
| October 07, 2026 | 211.37B |
| October 06, 2026 | 208.52B |
| October 05, 2026 | 208.01B |
| October 02, 2026 | 210.23B |
| October 01, 2026 | 212.05B |
| September 30, 2026 | 214.33B |
| September 29, 2026 | 215.47B |
| September 28, 2026 | 215.47B |
| September 25, 2026 | 215.19B |
| September 24, 2026 | 213.71B |
| September 23, 2026 | 212.39B |
| September 22, 2026 | 210.97B |
| September 21, 2026 | 209.89B |
| Date | Value |
|---|---|
| September 18, 2026 | 209.43B |
| September 17, 2026 | 209.32B |
| September 16, 2026 | 208.29B |
| September 15, 2026 | 208.80B |
| September 14, 2026 | 209.77B |
| September 11, 2026 | 209.77B |
| September 10, 2026 | 209.37B |
| September 09, 2026 | 210.12B |
| September 08, 2026 | 210.17B |
| September 04, 2026 | 213.93B |
| September 03, 2026 | 215.99B |
| September 02, 2026 | 217.18B |
| September 01, 2026 | 214.50B |
| August 31, 2026 | 213.99B |
| August 28, 2026 | 211.14B |
| August 27, 2026 | 211.48B |
| August 26, 2026 | 213.08B |
| August 25, 2026 | 214.62B |
| August 24, 2026 | 211.20B |
| August 21, 2026 | 211.77B |
| August 20, 2026 | 210.17B |
| August 19, 2026 | 212.74B |
| August 18, 2026 | 207.09B |
| August 17, 2026 | 204.93B |
| August 14, 2026 | 204.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
| Bristol Myers Squibb Co. | 159.59B |
| Viatris, Inc. | 33.01B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -246.00M |
| Revenue (Quarterly) | 15.03B |
| Total Expenses (Quarterly) | 15.29B |
| EPS Diluted (Quarterly) | -0.0435 |
| Gross Profit Margin (Quarterly) | 62.94% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 9.88% |
| Normalized Earnings Yield | 8.068 |